Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis (ESCAPE-NEXT)
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
Sponsor: NoNO Inc.
This PHASE3 trial investigates Stroke, Acute and is currently completed. NoNO Inc. leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Apr 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2022 — Apr 2023 [monthly]
Recruiting PHASE3
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NoNO Inc.
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Aarau, Switzerland , Abington, United States , Adelaide, Australia , Altenburg, Germany , Amsterdam, Netherlands , Atlanta, United States , Augsburg, Germany , Baltimore, United States , Basel, Switzerland and 65 more locations